The BPC-157 half-life in humans is unknown: no published human pharmacokinetic study has measured it. The best direct evidence comes from rats and beagle dogs. In a 2022 study, the average elimination half-life of intact BPC-157 was 15.2 minutes after intravenous administration in rats and 5.27 minutes in dogs; every measured intravenous or intramuscular condition was under 30 minutes. Those results do not establish a four-hour human half-life, a dosing interval, or the duration of any biological effect.
Half-life, onset and detection are separate questions. Half-life describes how quickly the measured concentration falls by half. It does not say when someone might notice a change; how long BPC-157 may take to work addresses that different question.
What the BPC-157 half-life data actually show
The only formal, peer-reviewed pharmacokinetic study measured BPC-157 in animals, not people. The 2022 Frontiers in Pharmacology study used intravenous and intramuscular administration in groups of six rats or six dogs. It found rapid uptake after intramuscular administration and rapid loss of the intact, or parent, peptide from plasma.
| Measurement | What the study found | What it does not establish |
|---|---|---|
| Human elimination half-life | No published measurement | A human value for injection or oral use |
| Rat, intravenous | 15.2 minutes on average | A subcutaneous or human half-life |
| Rat, intramuscular | 7.87–29.7 minutes across three studied doses | A clinical dosing schedule |
| Dog, intravenous | 5.27 minutes | A human duration of action |
The distinction between intact peptide and its remnants matters. In a radiolabeled rat experiment, the same paper reported a much longer signal for total radioactivity. The authors explained that this signal included degradation products such as smaller peptide fragments, proline and tritiated water. It was not a second half-life for intact BPC-157. Parent peptide was the main radioactive component at three minutes, then broke down rapidly.
Why gastric stability is not plasma half-life
BPC-157 is often called the stable gastric pentadecapeptide. Published laboratory literature describes the 15-amino-acid sequence as resistant to degradation in human gastric juice; that origin explains the name. It does not mean the peptide remains intact for the same length of time after entering blood. Gastric fluid and plasma contain different enzymes and present different chemical conditions.
This is also why route matters. The animal PK study tested intravenous and intramuscular administration. It did not measure subcutaneous or oral pharmacokinetics in humans. Evidence that a peptide remains intact in gastric juice does not, by itself, establish how much crosses the intestine into circulation. The evidence on oral BPC-157 needs to be read separately from injection data.
Why the four-hour number is not a dosing clock
The frequently repeated claim that BPC-157 has a four-hour half-life has no traceable primary study behind it. It does not appear in the peer-reviewed animal PK paper, and no published human PK paper supplies that value. Repetition across vendor pages is not independent confirmation.
Even a reliable short half-life would not automatically dictate how often a medication should be used. A drug can leave plasma before downstream signaling ends; conversely, a detectable concentration does not prove a continuing clinical effect. For BPC-157, the human exposure-response relationship has not been mapped, so a schedule cannot be calculated from the rat and dog numbers.
TB-500 is sometimes discussed beside BPC-157 in recovery protocols, but it is a different peptide and its kinetics cannot fill the BPC-157 evidence gap. BPC-157 and TB-500 dosing covers how schedule decisions are framed without turning an animal half-life into instructions. The actual dose and timing are set by the prescriber.
How long does BPC-157 stay in your system?
There is no validated human clearance or detection window. “Stay in your system” can refer to intact BPC-157, metabolites, or whether an anti-doping laboratory can identify either in urine. Those endpoints are not interchangeable.
A 2017 Drug Testing and Analysis paper developed a urine assay with a 0.1 ng/mL detection limit and found that BPC-157 was stable in collected urine for at least four days. That means the analyte survived in a stored sample; it does not mean a dose remains detectable in a person for four days.
A 2023 Molecules study used human liver microsomes and skin S9 fractions in vitro to identify nine metabolic products. It also validated an assay for parent BPC-157 and five metabolites in fortified human urine, with detection limits of 0.01–0.11 ng/mL. The study did not administer BPC-157 to people, so it cannot supply a post-dose testing window.
For athletes, the rule is clearer than the timeline. The 2026 World Anti-Doping Agency Prohibited List names BPC-157 under S0, substances prohibited at all times, both in and out of competition. An unknown detection window is not a safe interval.
What a clinical review can and cannot resolve
A clinician cannot convert animal minutes into a precise human half-life. A clinical review can account for formulation, route, medical history, other medications and the uncertainty in the evidence before any prescription decision. A licensed provider reviews every request, and not everyone qualifies.
This distinction matters when comparing prescribed compounded medication with a grey-market vial. A product-page half-life cannot verify identity, purity or concentration. Prescription-based care adds a clinician who is accountable for the decision and a licensed U.S. compounding pharmacy responsible for dispensing.
The research still needs a published human study that measures parent BPC-157 and metabolites over time after defined routes of administration. Until that exists, the honest answer remains narrow: animal plasma data point to rapid clearance of intact peptide, while the BPC-157 half-life in people is not known.